Financial News
New Crypto Pepeto Passes $8.25M While Dogecoin Price Prediction Heats Up and Elon Musk Confirms X Money Goes Live in April
Dubai, UAE, March 21, 2026 (GLOBE NEWSWIRE) -- Pepeto just cleared $8.25 million in presale and every signal around this new crypto is lining up in a way the market has witnessed only twice, once with Dogecoin and once with Shiba Inu, both just before Elon Musk turned them into global headlines.
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
4,056 articles
Top Pharmaceutical Stocks To Follow Today – March 20th
Eli Lilly and Company, AbbVie, Novo Nordisk A/S, Pfizer, and Abbott Laboratories are the five Pharmaceutical stocks to watch today, according to...
Best Growth Stocks To Follow Today – March 20th
Prologis, Teledyne Technologies, Ascendis Pharma A/S, Hercules Capital, Hamilton Lane, Tyra Biosciences, and Canopy Growth are the seven Growth...
Top Pharmaceutical Stocks To Follow Today – March 20th
Eli Lilly and Company, AbbVie, Novo Nordisk A/S, Pfizer, and Abbott Laboratories are the five Pharmaceutical stocks to watch today, according to...
Top Pharmaceutical Stocks To Follow Today – March 20th
Eli Lilly and Company, AbbVie, Novo Nordisk A/S, Pfizer, and Abbott Laboratories are the five Pharmaceutical stocks to watch today, according to...
Promising Medical Stocks To Research – March 20th
UnitedHealth Group, Eli Lilly and Company, Johnson & Johnson, Exact Sciences, Merck & Co., Inc., AbbVie, and Amgen are the seven Medical...
Gold Stocks To Consider – March 20th
Newmont, Freeport-McMoRan, Barrick Mining, Coeur Mining, Agnico Eagle Mines, Wheaton Precious Metals, and First Majestic Silver are the seven Gold...
Qiagen (NYSE:QGEN) Sets New 12-Month Low – Should You Sell?
Qiagen N.V. (NYSE:QGEN – Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $39.85 and last traded...
Terns Pharmaceuticals (NASDAQ:TERN) Reaches New 1-Year High – Should You Buy?
Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) shares reached a new 52-week high during trading on Friday . The company traded as...
SkinBioTherapeutics (LON:SBTX) Trading Down 34.6% – What’s Next?
SkinBioTherapeutics plc (LON:SBTX – Get Free Report) fell 34.6% on Friday . The stock traded as low as GBX 6.25 and last traded at GBX 6.28....
Oxford BioDynamics (LON:OBD) Stock Price Up 11.1% – Time to Buy?
Oxford BioDynamics Plc (LON:OBD – Get Free Report) shares traded up 11.1% during mid-day trading on Friday . The stock traded as high as GBX...
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) hit a new 52-week high during mid-day trading on Friday . The stock traded...
Scancell (LON:SCLP) Shares Down 3.1% – Here’s What Happened
Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price fell 3.1% on Friday . The company traded as low as GBX 11.63 and last...
Humana (NYSE:HUM) Reaches New 52-Week Low – Here’s What Happened
Humana Inc. (NYSE:HUM – Get Free Report) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $163.11 and...
Reviewing Peak Pharmaceuticals (OTCMKTS:PKPH) and Merck KGaA (OTCMKTS:MKGAF)
Earnings & Valuation This table compares Peak Pharmaceuticals and Merck KGaA”s top-line revenue, earnings per share and valuation. Gross...
Alvotech (NASDAQ:ALVO) Upgraded at Zacks Research
Zacks Research upgraded shares of Alvotech (NASDAQ:ALVO – Free Report) from a strong sell rating to a hold rating in a research report sent to...
Merck KGaA (OTCMKTS:MKKGY) Upgraded at Sanford C. Bernstein
Sanford C. Bernstein upgraded shares of Merck KGaA (OTCMKTS:MKKGY – Free Report) to a hold rating in a research note released on Thursday...
Sanofi (NASDAQ:SNY) Upgraded at Sanford C. Bernstein
Sanford C. Bernstein upgraded shares of Sanofi (NASDAQ:SNY – Free Report) to a strong-buy rating in a research report sent to investors on...
Citigroup Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock
Merck & Co., Inc. (NYSE:MRK – Get Free Report) had its price target boosted by Citigroup from $120.00 to $125.00 in a report issued on...
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028
Recursion Pharmaceuticals (NASDAQ:RXRX) Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery...
Mark Cuban Says AI Revolution Is Easier For White Collar Workers Than PC Revolution, Predicts Job Cuts At Big Companies
Billionaire entrepreneur Mark Cuban took to X to weigh in on the ongoing AI revolution and its potential effects on the workforce.
AI Mirrors PC...
📰
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears
This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings report.
📰
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Picard Medical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PMI
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
📰
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
📰
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
📰
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
📰
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
📰
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
📰
Is This Stock a Buy on the Dip?
This company has a habit of beating the market over long periods.
📰
Is This Stock a Buy on the Dip?
This company has a habit of beating the market over long periods.
📰
Switching from RBC Wealth Management to Fidelity/Schwab etc.
My family has dealt with our local RBC Wealth Management (USA) office for decades (going back through other pre merger companies). I like the office...
📰
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
📰
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
📰
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
📰
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
2 Beaten-Down Stocks That Still Aren't Worth Buying
These stocks aren't nearly as cheap as they look.
📰
2 Beaten-Down Stocks That Still Aren't Worth Buying
These stocks aren't nearly as cheap as they look.
📰
1 High-Yield Dividend Stock That's Too Cheap to Ignore
Sometimes "boring" is the way to go.
📰
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.
📰
INO FINAL DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS LAWYERS, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INO
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...